Newsroom

DALLAS--(BUSINESS WIRE)--D.A. Davidson & Co. announced today the continued expansion of its capital markets platform with the hire of John Baumgartner as Vice Chairman and Co-Head of Equity Capital Markets. Baumgartner will co-lead the group alongside Josh Nolan, focusing on the origination, marketing, pricing, and distribution of the firm's equity capital raising transactions. He will be based in the Greater Dallas area, further expanding D.A. Davidson's presence in the Texas market.Baumgar...

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Parisa Zamiri, M.D., Ph.D., to its board of directors. Dr. Zamiri's appointment comes as Qlaris continues to advance its lead development program, QLS-111, through late-stage clinical trials as a novel therapeutic agent for the treatment of glaucoma.Dr. Zamiri is a physician-scientist and ophthalmologist by traini...

MILWAUKEE--(BUSINESS WIRE)--Marcus Corporation (NYSE: MCS) today announced that Rajiv W. Castellino, chief technology officer of Marcus Hotels & Resorts, has been promoted to chief information officer of Marcus Corporation. Castellino will assume the role on August 2, 2026, succeeding Kim M. Lueck, who will retire as chief information officer on August 1, 2026, after nearly 30 years with the company. “Rajiv has consistently aligned technology strategies to drive revenue, improve efficiency,...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S....

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

KINSTON, N.C.--(BUSINESS WIRE)--flyExclusive, Inc. (NYSE American: FLYX), one of the largest private jet operators in North America — and the only fully integrated one — today announced that it has secured a $30 million grant from the State of North Carolina to expand its maintenance and repair operation and develop a new pilot training facility at the North Carolina Global TransPark in Kinston. The investment is expected to create more than one hundred new aviation jobs in Lenoir County and fur...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...